MTSR

1 BTC

=

- USD

Metsera, Inc. Common Stock logo

Metsera, Inc. Common Stock

MTSR🇺🇸
Coming Soon
0.00%

As of May 30, 2026 at 24:05 UTC

Chart

About Metsera, Inc. Common Stock

Sector
PHARMACEUTICAL PREPARATIONS
Headquarters
NEW YORK
Employees (FY)
109
Listed
2025-01-31
FIGI
BBG01MJLWZG3

Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.

Market Statistics

Market Capâ‚¿ 101.26K
24h Volume-
24h Change0.00%
7d Change0.00%
1m Change0.00%

Trading Metrics

Trading Volume (BTC)-

How to Buy MTSR

1

Create Your Account

Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.

2

Start Your Trade

From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.

3

Buy MTSR

Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.

New to Tokenized Assets? Learn more in our Help Center.

Latest News

5 articles
Benzinga favicon
Benzingawww.benzinga.com

Novo Nordisk lost a bidding war for Metsera to Pfizer but responded by cutting Wegovy prices in India to compete in the growing obesity treatment market.

Related:
GlobeNewswire Inc. favicon
GlobeNewswire Inc.www.globenewswire.com

Law firm Johnson Fistel launched an investigation into potential fiduciary duty breaches by Metsera's board regarding its proposed sale to Pfizer at $47.50 per share, which is significantly below Wall Street analyst projections.

Related:
The Motley Fool favicon
The Motley Foolwww.fool.com

Pfizer faces challenges with upcoming patent expirations for three blockbuster drugs in 2027-2028 and a complicated acquisition attempt of Metsera, creating uncertainty about its near-term financial outlook.

Related:
Benzinga favicon
Benzingawww.benzinga.com

A week of significant M&A activity featuring a founder's potential buyback, a heated pharmaceutical bidding war, media industry consolidation, and strategic partnerships in entertainment and aviation.

Benzinga favicon
Benzingawww.benzinga.com

Delaware Chancery Court denied Pfizer's request to prevent Metsera from terminating their merger agreement in favor of Novo Nordisk's competing proposal. Pfizer plans to raise its bid and challenges the legality of Novo Nordisk's transaction structure.

Related:

1 BTC

=

- USD

Loading market data...